Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) ADA & Neutralizing Antibody (NAb) Assay Service
Are you currently facing complex immunogenicity challenges in your preclinical studies, including the difficulty of accurate ADA/NAb detection in Non-Human Primate (NHP) models? Our NHP ADA & Neutralizing Antibody (NAb) Assays Service helps you streamline your drug development and obtain reliable, defensible data through our innovative, high-precision assay platforms and expert scientific team. We provide a tailored solution for your unique therapeutic protein.
The Critical Role of NHP Immunogenicity Assays
What Our Service Is
Immunogenicity is a key safety and efficacy concern for all protein-based therapeutics, including gene therapies and novel antibodies. The development of unwanted anti-drug antibodies (ADAs) or neutralizing antibodies (NAbs) can compromise a drug's effectiveness, alter its pharmacokinetics, and lead to adverse events. Non-Human Primates (NHPs) are the most relevant and predictive preclinical model for evaluating human immunogenicity due to their biological, genetic, and immunological similarities. Our NHP ADA & NAb Assays Service provides a comprehensive solution for detecting and characterizing these critical immune responses.
- Preclinical Safety Assessment: Fulfilling regulatory requirements by evaluating potential immunogenicity in a relevant animal model before first-in-human studies.
- Dose and Regimen Optimization: Using immunogenicity data to guide dose selection, identify appropriate dosing intervals, and inform patient stratification.
- Efficacy and PK/PD Correlation: Investigating the relationship between an immune response and a drug's efficacy and pharmacokinetic profile to ensure a comprehensive understanding of your therapeutic candidate.
Why Choose Us?
-
Pain Point: Drug Interference - Residual drug in samples masks a true ADA signal.
- Benefit: Proven Solutions: Our validated acid dissociation and sample treatment methods overcome drug tolerance, ensuring no ADA signal is missed.
-
Pain Point: Matrix Effects - Variability in NHP serum matrices causes assay instability.
- Benefit: Robust Optimization: Our double-blocking steps and extensive validation minimize matrix interference, providing consistently reliable data.
Key Benefits of Our Service
Creative Biolabs' NHP immunogenicity assay services stand apart due to our unwavering commitment to precision, customization, and scientific expertise.
- Rapid Response and Turnaround Time: Our streamlined workflows and dedicated project management ensure we accelerate your preclinical timelines without compromising on quality.
- Deep NHP Expertise: Our team's extensive experience with NHP models allows us to effectively manage challenges such as matrix interference and drug tolerance, which are common in these complex samples.
- Customization for Every Project: We work closely with you to design and validate a tailored assay that is specific to your drug product and its unique mechanism of action, ensuring the data is clinically relevant.
- Comprehensive Reporting: Beyond raw data, our final deliverables include detailed analysis, method validation summaries, and clear interpretations of the results. This depth of reporting provides actionable insights for your development team.
How Creative Biolabs' NHP Services Can Assist Your Project?
Our NHP ADA & NAb Assay services are designed as a clear and transparent process, ensuring you are informed at every stage, from initial consultation to final data delivery.
01
Required Starting Materials
02
Assay Feasibility & Development
03
Method Validation
04
Sample Testing
05
Data Analysis & Reporting
Key Deliverables
- Detailed Method Validation Report
- Comprehensive Final Study Report
- Raw Data Files
- Summary of Key Findings and Recommendations
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: What is the difference between an ADA and a NAb assay, and why do I need both?
A: An ADA assay detects if the body has produced antibodies that bind to your therapeutic protein, while a NAb assay specifically checks if those antibodies can neutralize the drug's biological function. Both assays are crucial because a positive ADA response doesn't always lead to a loss of efficacy, but a positive NAb response almost always does. A multi-tiered approach using both provides the most complete picture of your drug's immunogenicity profile.
Q: How does Creative Biolabs handle drug interference in immunogenicity assays?
A: Drug interference is a major challenge, especially with high-dose therapeutics. We have developed and validated specific sample treatment methods, such as acid dissociation, that separate ADAs from the drug-antibody complexes. This ensures we can accurately detect the ADA signal even when high levels of your therapeutic protein are present in the sample.
Q: Are your NHP assays customizable for my specific therapeutic protein?
A: Yes, absolutely. We believe that a customized assay is key to success. Our scientists work with you to understand your drug's unique mechanism of action and tailor the assay design to ensure it is highly specific, sensitive, and relevant to your preclinical study objectives. We don't just run samples; we partner with you to get the right data.
Q: What if our project timeline is very aggressive? Can you accommodate it?
A: We understand the pressures of drug development timelines. Our project management team is highly experienced in delivering projects efficiently without compromising data quality. While our standard TAT is 6-8 weeks, we invite you to discuss your specific needs with us. We will work to create a customized plan that aligns with your project's goals.
Q: What level of expertise does your team have in NHP studies?
A: Our team has decades of collective experience in preclinical bioanalysis, with a deep specialization in NHP models. We have encountered and successfully resolved a wide range of challenges, from matrix interference to complex drug tolerance issues.
Contact Us
Creative Biolabs is your trusted partner for navigating the complex world of immunogenicity. Our NHP ADA & Neutralizing Antibody (NAb) Assays Service combine cutting-edge technology with unparalleled scientific expertise to deliver actionable insights that de-risk your preclinical program. Don't let immunogenicity challenges slow down your development. Reach out to our expert team today to discuss your project's specific needs and learn how our customized solutions can help you succeed.